Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is it time to revise antiretrovirals dosing? A pharmacokinetic viewpoint

Published:2014-10-23 Issue:16 Volume:28 Page:2477-2480
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Cattaneo Dario,Baldelli Sara,Castoldi Simone,Charbe Nitin,Cozzi Valeria,Fucile Serena,Clementi Emilio

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference23 articles.

1. Efficacy of 400mg efavirenz versus standard 600mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind,placebo-controlled, noninferiority trial.;Puls;Lancet,2014

2. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement.;Crawford;Lancet Infect Dis,2012

3. Dose reduction of antiretrovirals: a feasible and testable approach to expand HIV treatment in developing countries.;Vento;Trop Med Int Health,2013

4. Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.;Ramautarsing;AIDS Res Ther,2010

5. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.;Rodriguez-Novoa;AIDS,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic drug monitoring of antiretroviral therapy: current progresses and future directions;Expert Review of Clinical Pharmacology;2024-06-04

2. Scientific Basis of Antiretroviral Therapy;Fundamentals of HIV Medicine 2021;2021-06

3. Does lopinavir really inhibit SARS-CoV-2?;Pharmacological Research;2020-08

4. Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?;Journal of Antimicrobial Chemotherapy;2020-05-14

5. Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation;Therapeutic Drug Monitoring;2020-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3